NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free ATAI Stock Alerts $1.67 -0.10 (-5.65%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.61▼$1.7950-Day Range$1.68▼$2.1952-Week Range$1.03▼$2.39Volume1.59 million shsAverage Volume1.58 million shsMarket Capitalization$277.24 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atai Life Sciences alerts: Email Address Atai Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside947.9% Upside$17.50 Price TargetShort InterestHealthy3.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.79 out of 5 starsMedical Sector457th out of 947 stocksPharmaceutical Preparations Industry215th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, Atai Life Sciences has a forecasted upside of 947.9% from its current price of $1.67.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.04% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 27.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATAI. Previous Next 2.8 News and Social Media Coverage News SentimentAtai Life Sciences has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Atai Life Sciences this week, compared to 1 article on an average week.Search Interest21 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 110% compared to the previous 30 days.MarketBeat Follows7 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.16% of the stock of Atai Life Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atai Life Sciences are expected to remain at ($0.67) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Atai Life Sciences Stock (NASDAQ:ATAI)ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More ATAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATAI Stock News HeadlinesMarch 15, 2024 | morningstar.comThinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?March 14, 2024 | finance.yahoo.comCaris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's CancerMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 14, 2024 | msn.comPsychedelic drug ibogaine hailed as healing. U.S. patients ask why it’s illegal.March 12, 2024 | finance.yahoo.comatai Life Sciences advances VLS-01 for treatment-resistant depressionMarch 8, 2024 | finance.yahoo.comATAI Apr 2024 1.500 putMarch 8, 2024 | finance.yahoo.comATAI Apr 2024 2.000 callMarch 4, 2024 | proactiveinvestors.comatai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulationMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 4, 2024 | globenewswire.comatai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01February 28, 2024 | globenewswire.comatai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comATAI Life Sciences Stock (NASDAQ:ATAI), Quotes and News SummaryFebruary 17, 2024 | finance.yahoo.comATAI Mar 2024 2.000 callFebruary 15, 2024 | finance.yahoo.comATAI Feb 2024 1.500 putFebruary 15, 2024 | finance.yahoo.comATAI Mar 2024 1.500 putFebruary 15, 2024 | finance.yahoo.comATAI Aug 2024 1.500 callFebruary 14, 2024 | theglobeandmail.comBreaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSDFebruary 7, 2024 | msn.comATAI Life Sciences Announces New CFO Appointment and TransitionFebruary 6, 2024 | marketwatch.comAtai Life Sciences Names Anne Johnson CFOFebruary 6, 2024 | finance.yahoo.comatai Life Sciences Appoints Anne Johnson as Chief Financial OfficerFebruary 2, 2024 | msn.comMeet the family leading the psychedelic revolutionJanuary 6, 2024 | msn.comAtai buys 35.5% stake in psychedelic drug developer, stock rallies 18%January 5, 2024 | finance.yahoo.comEcstasy-for-Medicine Advocate Raises $100 MillionJanuary 4, 2024 | ca.investing.comatai Life Sciences expands its pipeline with $50M investment in Beckley PsytechJanuary 4, 2024 | msn.comAtai Invests $50M In Beckley Psytech For Short-Duration Psychedelics DevelopmentJanuary 4, 2024 | msn.comAtai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD TreatmentJanuary 4, 2024 | bloomberg.comBerliner Psychedelika-Firma Atai kauft Anteil an Beckley PsytechSee More Headlines Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today3/18/2024Next Earnings (Estimated)3/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$20.00 Low Stock Price Target$15.00 Potential Upside/Downside+947.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,380,000.00 Net Margins-20,043.11% Pretax Margin-18,050.30% Return on Equity-54.90% Return on Assets-47.37% Debt Debt-to-Equity Ratio0.06 Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$230,000.00 Price / Sales1,205.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.04Miscellaneous Outstanding Shares166,010,000Free Float116,207,000Market Cap$277.24 million OptionableOptionable Beta0.97 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Christian Angermayer (Age 46)Founder & Chairman of the Supervisory Board Comp: $70kMr. Florian Brand (Age 37)Co-founder & CEO Comp: $835.44kDr. Srinivas G. Rao M.D. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Comp: $834.15kMr. Stephen B. Bardin (Age 33)Advisor Comp: $651.32kMs. Anne JohnsonChief Financial OfficerDr. Michael Raven Ph.D.Senior Vice President of OperationsMr. Frank Stegert (Age 43)Vice President of Investment & Venture Management Mr. Ryan BarrettSenior VP, General Counsel & Corporate SecretaryDr. Glenn Short Ph.D.Senior Vice President of Early DevelopmentDr. Sahil V. Kirpekar M.D. (Age 39)Chief Business Officer More ExecutivesKey CompetitorsGossamer BioNASDAQ:GOSSNanobiotixNASDAQ:NBTXAdlai NortyeNASDAQ:ANLErascaNASDAQ:ERASEnanta PharmaceuticalsNASDAQ:ENTAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 113,729 shares on 3/11/2024Ownership: 0.247%Goldman Sachs Group Inc.Bought 55,002 shares on 3/1/2024Ownership: 0.067%Virtu Financial LLCBought 29,140 shares on 2/26/2024Ownership: 0.018%Prelude Capital Management LLCBought 17,952 shares on 2/15/2024Ownership: 0.011%Citadel Advisors LLCSold 4,800 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ATAI Stock Analysis - Frequently Asked Questions Should I buy or sell Atai Life Sciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks. What is Atai Life Sciences' stock price target for 2024? 2 Wall Street analysts have issued 1-year target prices for Atai Life Sciences' shares. Their ATAI share price targets range from $15.00 to $20.00. On average, they anticipate the company's share price to reach $17.50 in the next year. This suggests a possible upside of 947.9% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts. How have ATAI shares performed in 2024? Atai Life Sciences' stock was trading at $1.41 at the beginning of 2024. Since then, ATAI stock has increased by 18.4% and is now trading at $1.67. View the best growth stocks for 2024 here. Are investors shorting Atai Life Sciences? Atai Life Sciences saw a drop in short interest in February. As of February 29th, there was short interest totaling 3,530,000 shares, a drop of 27.5% from the February 14th total of 4,870,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is presently 2.5 days. Currently, 3.0% of the shares of the stock are sold short. View Atai Life Sciences' Short Interest. When is Atai Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024. View our ATAI earnings forecast. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.21). The business earned $0.17 million during the quarter. Atai Life Sciences had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 20,043.11%. What ETFs hold Atai Life Sciences' stock? ETFs with the largest weight of Atai Life Sciences (NASDAQ:ATAI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI). What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO). When did Atai Life Sciences IPO? (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.38%), Vanguard Group Inc. (0.25%), Vanguard Group Inc. (0.25%), Barclays PLC (0.15%), AdvisorShares Investments LLC (0.12%) and Goldman Sachs Group Inc. (0.07%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATAI) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.